Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Death/intubation 81% c19early.com/aa Vicenzi et al. Antiandrogens for COVID-19 LATE Favors antiandrogen Favors RAAS inhibit..
Vicenzi, 69 patient canrenone antiandrogen late treatment study: 93% lower mortality [p<0.0001] and 81% lower combined mortality/intubation [p=0.002] https://c19p.org/vicenzi
copied to clipboard
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Vicenzi et al., Journal of Clinical Medicine, doi:10.3390/jcm9092943
11 Sep 2020    Source   PDF   Share   Tweet
Retrospective 69 consecutive hospitalized COVID-19 patients in Italy, 30 patients receiving canrenone, and 39 treated with vasodilator agents or renin–angiotensin–aldosterone system (RAAS) inhibitors, showing lower mortality with canrenone.
risk of death, 93.0% lower, HR 0.07, p < 0.001, treatment 30, control 39, adjusted per study, model 2, multivariable.
risk of death/intubation, 81.0% lower, HR 0.19, p = 0.002, treatment 30, control 39, adjusted per study, model 2, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vicenzi et al., 9/11/2020, retrospective, Italy, Europe, peer-reviewed, 10 authors, this trial compares with another treatment - results may be better when compared to placebo.
Contact: marco.vicenzi@unimi.it (corresponding author), massimiliano.ruscica@unimi.it (corresponding author), irene.rota85@gmail.com, angelo.ratti.91@gmail.com, dicosola.roberta@gmail.com, alberto.corsini@unimi.it, simona.iodice@unimi.it, valentina.bollati@unimi.it, stefano.aliberti@unimi.it, francesco.blasi@unimi.it.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit